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In this paper we study the feasibility of estimating a monetary value for a QALY (MVQ). 
Using two different surveys of the Spanish population (total n=892), we consider 
whether willingness to pay (WTP) is (approximately) proportional to the health gains 
measured in QALYs. We also explore whether subjects’ responses are prone to any 
significant biases. We find that the estimated MVQ varies inversely with the magnitude 
of health gain. We also find two other (ir)regularities: the existence of ordering effects; 
and insensitivity of WTP to the duration of the period of payment. Taken together, these 
effects result in large variations in estimates of the MVQ. If we are ever to obtain 
consistent and stable estimates, we should try to understand better the sources of 
variability found in the course of this study. 
JEL: I10, I18 
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1. Introduction 
 
Much cost-effectiveness and cost-utility analysis has been undertaken to guide health care 
resource allocation. However, if we wish to go further and conduct cost-benefit analysis – 
and thereby make health care resource allocation more directly comparable with decision 
making in other areas of public policy – we need to find some way of attaching monetary 
values to health benefits. Since much of the health benefit measurement to date has been 
conducted in terms of Quality Adjusted Life Years (QALYs), one solution – were it to be 
feasible – would be to estimate the monetary value of a QALY (henceforth, the MVQ).  
 
In the UK, the National Institute for Health and Clinical Excellence (NICE) recognised 
the desirability of having such an estimate and recently commissioned a study to explore 
its feasibility. Others, too, have recognized the potential value of such a figure: for 
example, Johanesson and Meltzer (1998) considered that obtaining this information 
“should be a research priority” (p. 4). They identified two possible strategies for deriving 
the Willingness to Pay (WTP) per QALY gained. One would be based on direct 
elicitation of WTP for some marginal health change(s), while the other would derive this 
figure from estimates of the value of statistical life (VSL) in the literature. Some work of 
this latter kind has been attempted
1, but the present study focuses instead on the 
possibility of estimating the MVQ on the basis of eliciting people’s WTP for a range of 
health benefits. 
 
We acknowledge the possibility that estimating a unique MVQ may not be feasible. 
Several papers, including Bleichrodt and Quiggin (1999) and Dolan and Edlin (2002), 
have shown that the conditions for a unique MVQ to exist are quite restrictive and are 
unlikely to hold. However, our objective was to explore just how stable – or variable – 
such an estimate might be. Our strategy was to use changes that were small relative to 
those used in other studies in this area
2 in the hope that budget constraints would not 
cause significant nonlinearities
3.   
 
Abellan-Perpiñan et al. (2006) and Bleichrodt and Pinto (2005) have suggested that a 
non-linear QALY model may be better than the linear model. If non-linearities are 
important, this may result in estimates of the MVQ varying considerably according to the 
basis upon which they are derived. So we wished to check for the possible impact of 
various non-linearities with respect to severity, duration and the size of risk reduction. 
 
Our empirical work involved two surveys. The first, and larger, of these was designed to 
investigate several issues fundamental to the robust estimation of a reasonably stable 
MVQ. The second survey was designed to follow up and clarify certain issues raised by 
the results of the first. 
 
 
                                                 
1 Hirth et al. (2000); Mason et al. (2008) 
2 For example, Byrne et al. (2005), King et al. (2005), Gyrd-Hansen (2003). 
3 It is always difficult to know how far people feel they are coming up against serious budget constraints, 
but by using smaller changes than previous studies, we aimed to attenuate this problem.   3
2. Broad Structure of the Study 
 
Before describing the particular features of each study, we set out the general framework 
within which we are working and according to which we shall derive the MVQ estimates. 
 
The basic idea of a QALY is to provide a measure that facilitates comparisons across a 
broad spectrum of health benefits. Ideally, it allows health care decision makers to weigh 
the total benefit of an intervention that alleviates short-term conditions involving 
moderate adverse effects against other interventions addressing more severe acute 
conditions, or chronic conditions of varying degrees of severity, or conditions that 
threaten to substantially reduce life expectancy. A monetary value of a QALY should 
therefore be robust across such a spectrum. 
 
So in the first survey, we were concerned to focus on the stability (or otherwise) of the 
MVQ with respect to: 
 
Variations in the severity of different conditions; 
Variations in the duration of a given condition; 
Variations in reductions in the risk of chronic conditions involving a substantial total 
loss of quality of life. 
 
Aware that WTP studies in related areas have been found to be vulnerable to various 
procedural effects (for examples, see Bateman et al. (2002)), we checked for any possible 
impact of the order in which questions were asked and the period over which the notional 
monetary payment was ‘collected’.  
 
In the light of questions raised about the relationship between the estimated MVQ and the 
magnitude of the health gain, we conducted a second smaller (but still substantial) survey 
to provide further information about that particular key issue. 
 
 
2.1 Questions and scenarios 
 
The studies revolved around questions which took the following general form. 
Respondents were asked to assume that they had been diagnosed with a particular illness 
that would, if untreated, put them in a specified impaired health state for the rest of their 
lives. They were told that there was a medicine (treatment A) which, if taken for 1 year, 
would cure this illness. The cost of this medicine for the patient was zero. They were told 
that it took some time for the medicine to take effect: 2 months in some cases, 4 months 
in other cases. They were also informed that there was another medicine (treatment B) 
that also cured the chronic problem but that was better than A. By “better” we meant one 
of several things: a) that it worked immediately, so that the impaired health state would 
not be experienced at all; b) that it reduced the duration of symptoms from 4 months to 2 
months; or c) that it reduced the severity of the symptoms but did not change the 
duration. 
   4
In all the above cases, the respondents were asked to consider the prognoses as certain: 
i.e. the diagnosis was certain and the effects of the treatments were certain. But there was 
also a form of question involving risk, where respondents were asked to assume that they 
faced a 1% chance of developing an illness which could put them in an impaired health 
state for the rest of their lives. They were then told that they could take a medicine that 
could reduce the risk, in one case from 1% to 0% and, in another case, from 1% to 0.5%. 
 
For all scenarios, they were told that neither of the medicines had side effects and that 
both had to be taken for a year. However, in all cases the better treatment involved some 
monetary cost for them. Their willingness to pay for the extra benefits of the better 
treatment was then elicited.   
 
In order to investigate the relationship between MVQ and the different factors being 
varied, we considered a total of 11 different scenarios, or ‘Types’, as set out in Table 1.  
 
We used three Euroqol (EQ-5D) health states to represent different quality of life levels. 
EQ-5D is a standardised instrument widely used in the computation of QALYs. It has 
five dimensions, with three levels on each dimension – no problems (1), moderate 
problems (2) and severe problems (3). So 11111 signifies being in good health with no 
abnormal problems on any dimension, while 21212 represents moderate problems on 
some dimensions and 22223 represent moderate problems on most dimensions, with 
severe problems on the fifth dimension (anxiety/depression). The two impaired health 
states 21212 and 22223 were chosen because piloting showed that they were not so 
severe as to create complications with negative scores
4 but were not so mild that many 
respondents would refuse to accept any risk of death to avoid them.  
 
In all cases where the prognosis and effects of treatment were certain, the duration of the 
health problems was short (4 months, 2 months, 2 weeks); alternatively, when the 
prospect was chronic (rest of life), the baseline risk of the health problem was small. 
Thus, for example, Type 1 was a scenario where, given the ‘default’ Treatment A (which 
cost the respondent nothing in monetary terms), she would experience impaired health 
state 22223 for 4 months before the treatment restored her to full health, whereas 
Treatment B would work immediately, thereby avoiding the 4 months in that impaired 
state. Type 2, by contrast, supposed that Treatment B would not work immediately but 
would reduce the period spent in 22223 from 4 months to 2 months.  
 
                                                 
4 Scores below zero signify that the respondent considers a state to be worse than being dead.   5
Table 1. Treatment Choice Scenarios Used in First Survey 
 
Type  Original state  Treatment A  Treatment B 
1  22223, rest of 
life 
4 months in 22223, 
then move to 11111
Immediately move to 
11111 
2  22223, rest of 
life 
4 months in 22223, 
then move to 11111
2 months in 22223, 
then move to 11111 
3  22223, rest of 
life 
2 months in 22223, 
then move to 11111
Immediately move to 
11111 
4  22223, rest of 
life 
2 months in 22223, 
then move to 11111
2 months in 21212, 
then move to 11111 
5  21212, rest of 
life 
4 months in 21212, 
then move to 11111
Immediately move to 
11111 
6  21212, rest of 
life 
4 months in 21212, 
then move to 11111
2 months in 21212, 
then move to 11111 
7  21212, rest of 
life 
2 months in 21212, 
then move to 11111
Immediately move to 
11111 
8  22223, rest of 
life 
2 weeks in 22223, 
then move to 11111
Immediately move to 
11111 
9  21212, rest of 
life 
2 weeks in 21212, 
then move to 11111
Immediately move to 
11111 
10 
1% risk of 
(22223, rest of 
life) 
Stay with original 
risk 
Eliminate risk of 
(22223, rest of life) 
11 
1% risk of 
(22223, rest of 
life) 
Stay with original 
risk 
Reduce to 0.5% the risk 
of (22223, rest of life) 
12 
1% risk of 
(21212, rest of 
life) 
Stay with original 
risk 
Eliminate risk of 
(21212, rest of life) 
13 
1% risk of 
(21212, rest of 
life) 
Stay with original 
risk 
Reduce to 0.5% the risk 
of (21212, rest of life) 
 
 
Types 10-13 inclusive are the ‘risk scenarios’, involving either the elimination of the 
baseline 1% risk (Types 10 and 12) or halving that baseline (Types 11 and 13) for chronic 
conditions involving either a lifetime of 22223 (10 and 11) or a lifetime of 21212 (12 and 
13). The various permutations of benefit in terms of Quality of Life (QoL) improvement, 
duration and probability can be seen in the right hand columns.  6
2.2. Computing the Monetary Value of a QALY 
 
With the scenarios described in Table 1 we can investigate the feasibility of estimating a 
reasonably robust MVQ. 
 
To illustrate, suppose a health care decision maker is considering the benefit to her 
constituent population of providing (let us say) 6,000 more Treatment B’s of Type 1. 
Each such treatment would reduce the period spent in state 22223 by 4 months, and so 
would represent a total of 2,000 years of people’s time during which the affected people 
had a higher QoL to the extent that 11111 is better than 22223. If we can measure the 
QoL improvement on a scale where 0 represents ‘as bad as being dead’ and 1 represents 
‘full health’, we can ‘quality adjust’ those 2,000 years accordingly: for example, if the 
QoL improvement were indexed at 0.6 (i.e. involved moving people from 0.4 to 1), the 
overall benefit would be judged to be 0.6 x 2,000 = 1,200 QALYs. 
 
If a representative cross-section of the constituent population were willing, on average, to 
pay Y€ for a single such treatment, this would give a total value of 6,000Y€ for the whole 
programme of interventions which, collectively, would yield 1,200 QALYs. From this we 
can derive an estimate for the MVQ: in this example, each QALY would be worth 5Y€. 
Analogous calculations can be undertaken for Types 2 – 9 to examine the stability of 
estimates across different scenarios. 
 
For Types 10 – 13, the estimation procedure is similar, but slightly modified. To 
illustrate, take Type 11. If 6,000 such interventions were delivered, each reducing the risk 
of the chronic condition from 1% to 0.5%, we should expect the overall effect to be, on 
average, the prevention of 30 chronic illnesses: that is, 30 people who would otherwise 
have been in health state 22223 for the rest of their lives would instead be in state 11111
5. 
In order to compute the QALY value of this intervention, we need to know not only the 
index number measuring the QoL difference between 11111 and 22223 but also the 
remaining life expectancy to which the difference applies: were it to be the case, for 
example, that the representative recipient had 40 years remaining, the QALY benefit 
would be 40 x 0.6 = 24 per successful treatment, giving an overall total QALY gain of 
720. On the basis of these purely illustrative numbers, the MVQ from questions about 
Type 11 scenarios would be found by dividing the total WTP of 6,000 representative 
respondents to this question by the total expected QALY gain of 720. 
 
On this basis, we can set out and test the following ‘null hypotheses’ as follows: 
 
1. MVQ is constant for any duration. This is tested by comparing Types where the QoL 
gain is the same but durations differ (e.g. Types 1 vs 2 or 5 vs 6).  
 
                                                 
5 In reality, of course, things are not quite so straightforward: ideally what we should compare is the health 
state profile for the person who suffers the chronic illness with their ‘clone’ who avoids this illness as a 
result of the intervention (but who may experience other health impairments during the rest of their life that 
mean they may not be in state 11111 for the whole of that time – just as the person who succumbs to the 
chronic condition may also experience other illnesses/impairments on top of that condition).   7
2. MVQ is constant for any change in QoL. This is tested using pairs where durations are 
the same but QoL gains differ (e.g. Types 1 vs 5 or 3 vs 4). 
 
3. MVQ is constant for any risk reduction. This is tested directly by comparing Types 10 
vs 11 or 12 vs 13; and the estimates derived via these questions can also be compared 
with those using certainty, based on Types 1 – 9. 
 
All these tests are within-Group tests. All of them rest on the assumption that these health 
changes are small enough for the utility function to be approximately linear in the 




2.3 The Questionnaires 
 
The questionnaires of both surveys had a similar structure, involving four parts: 
 
1. Introduction 
This explained the general objective of the survey and familiarised respondents with the 
health states under consideration by asking them to rate each state on a scale from 0 to 
10. 
 
2. Standard Gamble 
 
Utilities for health states 21212 and 22223 were elicited using the Standard Gamble (SG) 
procedure. Each SG question started by asking subjects if they would accept a 50% 
chance of death in order to avoid the chronic health problem. A ‘ping-pong’ procedure 
followed: if a subject rejected a particular level of risk, that probability was reduced and 
the question was asked again: if a subject accepted a particular level of risk, that 
probability was increased and the question was asked again. In that way, the procedure 
‘homed in’ on the risk of death that made the individual indifferent between the two 
alternatives. Denoting the ‘indifference risk of death’ for chronic state 22223 by p and the 
corresponding risk for 21212 by q, the utility scores assigned to those states for that 
individual are then 1-p for 22223 and 1-q for 21212. 
 
3. WTP questions 
 
The method used to elicit WTP was a card sorting procedure. The cards that were offered 
to subjects were monthly instalments of 6€, 12€, 18€, 30€, 45€, 60€, 90€, 120€, 180€, 
240€ and 300€
6 which they would (in most treatments) have to pay for one year. The 
interviewer was instructed to shuffle the cards in front of respondents to reassure them 
that there was no significance to the card that appeared first, or the order in which 
                                                 
6 In the second survey we also used cards featuring monthly payments of 450€ and 600€.   8
subsequent cards appeared
7. Respondents were then asked to identify the amounts that 
they were willing to pay, those they were not willing to pay and those they were not sure 
about. Those who said they were willing to pay all of the amounts presented to them were 
asked how much more they would pay. 
 
4. Sociodemographic questions 
 




3. First survey 
 
Respondents were 560 members of the general population. They were contacted by 
telephone through random dialing and those who agreed to be interviewed were visited 
by an interviewer. They were then assigned at random to one of the seven groups 




Of the 13 Types listed in Table 1, we used 11 in this first survey: that is, all of them 
except 8 and 9: the 2 week duration was only addressed in the second survey. The 11 
Types were organised into three main blocks which we shall call A, B and C. Within each 
block we used two different orders when asking WTP questions: as far as possible, the 
guiding principle was that half of those in each block were presented with questions 
where they saw the largest health gains first and the smallest health gains last, while for 
the other half it was the other way round
8. This generated six groups. A seventh 
subsample arose from the distinction between Group A-1 and Group A-3. Respondents in 
these two groups saw exactly the same scenarios in exactly the same order, but Group A-
3 were told that they would pay for Treatment B each month for 24 months, whereas 
those in Group A-1 (and in all other Groups) were told to suppose that their payment 
would be collected in the form of 12 monthly amounts: the purpose of this manipulation 
was to see how sensitive overall WTP was to the period of payment. 
 
                                                 
7 The intention was to try to control for any possible ‘starting point’ or ‘range’ effects – although, as 
Bateman et al. (2002) have indicated, it may not always be possible to eradicate such effects. Still, by 
adopting this randomised order, we can at least distribute any bias more or less equally across the groups. 
8 As will become clear, it is not always possible to rank health gains unambiguously: the important point, 
though, is that in all cases we tested for the independence of answers to the order in which questions were 
asked.   9
Table 2: WTP Questions and their Order for Each Subsample Group. 
  Order 1 – large to small    Order 2 – small to large
Group A-1 
Group A-3 
1. [Type 3] 
2. [Type 7] 
3. [Type 4] 
Group  A-2
1. [Type 4] 
2. [Type 7] 
3. [Type 3] 
Group B-1 
1. [Type 1] 
2. [Type 5] 
3. [Type 2] 
4. [Type 6] 
Group B-2 
1. [Type 6] 
2. [Type 2] 
3. [Type 5] 
4. [Type 1] 
Group C-1 
1. [Type 10] 
2. [Type 12] 
3. [Type 11] 
4. [Type 13] 
Group C-2 
1. [Type 13] 
2. [Type 11] 
3. [Type 12] 
4. [Type 10] 
 
In addition to the hypotheses numbered 1-3 in section 2.2 above, we used this first survey 
to check for invariance with respect to procedure and to test three further ‘null 
hypotheses’ as follows: 
 
4. MVQ estimates from any question are independent of the order of questions. This is 
tested by comparing A-1 vs A-2, B-1 vs B-2 and C-1 vs C-2.  
 
5. MVQ estimates are independent of the number of payment instalments. This is tested 
by comparing groups A-1 and A-3. 
 
6. Finally, we also checked for any systematic differences between ‘direct’ and ‘indirect’ 
ways of eliciting QoL indices. In the A Groups, we also elicited the utility of 21212 with 
respect to health state 22223. That is, subjects were faced with the choice between, on the 
one hand, spending the rest of life in health state 21212, or alternatively taking a medical 
treatment which, if successful, would put them in full health but which, if it failed, would 
worsen their health to 22223. Let the individual’s ‘indifference risk of 22223’ be denoted 
by r: then in these Groups, the utility of state 21212 was estimated directly as 1-q, and 
also indirectly, by ‘chaining’ via health state 22223, as 1-rp. This provides one further 
check on procedural invariance and the possible impact on estimates of MVQ 
 
3.2 Results 
Groups A-1, A-2 and A-3 
 
These Groups provide some of the tests of whether the MVQ is invariant with respect to 
the size of QoL change used to elicit it. They also allow us to examine all three ways in 
which procedural invariance might fail: order effects; insensitivity to period of payment; 
and differences between direct and indirect utility indices for 21212. Table 3 reports the 
relevant Group means. 
   10
Table 3: Mean WTP per month (€) for Treatment B and Mean Health State Utilities from SG 
Questions. In Groups A-1 and A-2 the duration of payment was 1 year and in Group A-3 it was 2 
years.  
  A-1  A-2  A-3  A-1 vs A-2 A-1 vs A-3 
WTP for treatment B
         
Type 3  112.32 60.13 103.61 * ns 
Type 7  59.65 35.48 46.90 * ns 
Type 4  67.55 26.38 60.93 * ns 
Utilities         
State 22223  0.703 0.758 0.728  ns ns 
State 21212 – direct  0.854 0.883 0.861  ns ns 
State 21212 – indirect  0.935 0.947 0.922  ns ns 
* There are statistically significant differences at the1% level using the t-test; 
ns = not significant at the 5% level  
 
We can see that: 
 
There are important order effects (comparison of Groups A-1 and A-2). When we start 
with the lowest health gain WTP is lower. 
 
Monthly WTP is insensitive to the period of payment (comparison of Groups A-1 and A-
3). 
 
The chained procedure produces higher utilities (p<0.001) than the direct procedure. This 
is a well-known result in the literature (Stalmeier, 2002)  
 
Given the doubts about procedural invariance, we cannot simply pool data from the 
different A Groups in order to estimate MVQs. We therefore keep them separate and 
report the various implied mean MVQs in Table 4. In each case, the point estimates have 
been calculated by combining the means of WTP responses and the mean estimates of the 
QoL improvements.  
 
The method of calculation can be illustrated with respect to the top-left entry in Table 4. 
For Group A-1, the mean monthly WTP to move from 22223 to 11111 for 2 months is 
112.33€. Multiply this by 12 to give the total WTP of 1,347.84€. This is the mean WTP 
for a health improvement worth, on average, a utility gain of 0.297 (i.e. from 0.703 to 
1.000) for one-sixth of a year: that is, a QALY gain of 0.04956. This gives MVQ = 
1,347.84€/0.04956 = 27,192€. The confidence intervals have been obtained by the bias-
corrected and accelerated percentile method (Efron 1987). This approach is widely used 
in the field of health economics to estimate non-parametric bootstrap confidence intervals 
of incremental cost-effectiveness ratios (Briggs et al. 1997, Tambour and Zethraeus 1998, 
Lord and Asante 1999, Barber and Thompson 2000). The null hypothesis of equality 
between MVQs can be tested by bootstrapping differences from the samples and by 
obtaining an approximate one-sided significance level of the differences by calculating 
the proportion of negative values in the vector of differences (Efron and Tibshirani 1993). 
We will use a 10% significance level in all cases (i.e. for A groups here, and in due   11
course for B and C Groups). In Table 4, the distinction between figures based on direct 
estimates of the utility of 21212 and indirect/‘chained’ estimates is indicated by the 
qualifiers ‘dir’ and ‘ind’ added to the Type label. 
 
Table 4: Mean MVQs  and 95% confidence intervals in Groups A-1, A-2 and A-3 
MVQ 






3  27,192 
(21,509-33,963) 
17,898 
 (14,564-21,963)  
54,803 
(47,830-63,164) 




63,032    
 (52,103-82,189)  






4dir  28,393 
(19,626-43,342) 
20,454    
 (15,772-26,249)  
50,755    
 (41,954-62,773)







We can see that the violations of procedural invariance – order effects, payment period 
effects and SG ‘chaining`effects – produce a very high volatility in MVQ estimates. 
These range from 18,000€ to 112,000€. All MVQ comparisons between groups for the 
same Type were statistically different at the 1% level. If we apply this result to the 
comparison between A-1 and A-2 this shows evidence of order effects.  If we apply this 
result to the comparison between A-1 and A-3 this shows evidence of insensitivity to the 
duration of payment. Within each group, MVQ values for the indirect method (7ind, 
4ind) were statistically significant at the 1% level from the rest of the MVQ estimates. If 
we focus on the estimates based on the direct method, the picture is mixed. In group A-1 
MVQ for the smallest health gain (Type 7dir) is smaller and statistically different 
(p=0.055) from the MVQ of the largest health gain (Type 3). This suggests that MVQ 
varies with the change in QoL. However, the differences between Type 3 and 7dir for 
group 2 is not statistically significant (p=0.262), whereas for group A-3 there is a 
significant difference at the 10% level (p=0.094). Overall, there is a tendency for the 
MVQ to be higher the smaller the size of the health gain.  
 
However, as a test of the sensitivity or otherwise of MVQ estimates to different changes 
in QoL, we should bear in mind that on the basis of the direct method, there is very little 
variability across the QoL differences. In direct utility terms, going from 22223 to 21212 
is roughly the same as going from 21212 to 11111 – the two mean differences are 0.151 
and 0.146 for A-1, 0.125 and 0.117 for A-2 and 0.133 and 0.139 for A-3. As it turned out, 
the QoL utility differences in these cases are so close that they do not provide a very 
searching test of the stability of MVQ estimates in the face of rather different QoL 
improvements.  
   12
Groups B-1 and B-2 
 
These two groups provide further evidence about order effects and the impact of different 
QoL changes on MVQs, but they were also intended to shed light on the stability of 
MVQs with respect to different durations of benefit. Mean WTP and directly elicited 
health state utilities are reported in ¡Error! No se encuentra el origen de la 
referencia.5. These convert into the MVQ estimates reported in the same table. 
 
Table 5: Mean WTP per month (€) for treatment B, mean utilities and MVQ (€).Groups 
B-1 and B-2 
Type  Mean WTP for treatment B p  MVQ 
 B-1  B-2    B-1  B-2 
1 156.93  78.3  *  20,158 
(16,684-24,413) 
8,881   
(7,306-10,770) 
2 102.19  44.95  *  26,253   
(20,392-33,068) 
10,197   
(8,508-12,310) 
5 111.58  51.39  *  30,574   
(22,716-42,695)   
10,685 
 (8,037-14,548) 




 Mean  utilities       
State 22223  0.720  0.683 ns    
State 21212  0.869  0.827 ns    
* Statistically significant differences between B-1 and B-2 at the 1% level using the t-test. 
 
 
First, as we found with the A Groups, the order effects are all statistically significant and 
all work in the same direction as with the A Groups.  On a within-Group basis, however, 
there appears at first sight to be some sensitivity of monthly WTP to the duration of the 
benefit: in comparisons between Types 1 and 2 and between Types 5 and 6, halving the 
duration of benefit is associated with noticeable reductions in both mean and median 
WTP responses. However, the reductions are generally less than proportional, so that the 
MVQs in Table 5 derived from the shorter durations are significantly higher (p<0.01) in 
three of the four comparisons (the exception being Types 5 vs 6 in B-2). Moreover, 
comparing Types 1 vs 5 and 2 vs 6 in both groups leads us to reject the null hypothesis 
that MVQs are invariant to the size of QoL gain. In the case of Type 1 vs 5, differences 
are statistically significant at the 1% level. In the case of Type 2 vs 6, differences were 
statistically significant for group B-1 at the 5% level (p=0.049) and at the 10% level for 
B-2 (p=0.062). In conclusion, there may have been some ambiguity on this issue in the A 
Group data, but here the picture is rather sharper: when MVQs are derived from larger 
health gains (22223 Æ 11111) as compared with smaller gains (21212 Æ 11111), the 
estimates are significantly smaller. The effect is more muted for B-2, but it is quite clear 
and strong for B-1.   13
Groups C-1 and C-2 
 
These two groups were intended to shed light on the stability of MVQs with respect to 
different risk reductions. Mean WTP and directly elicited health state utilities are 
reported in ¡Error! No se encuentra el origen de la referencia.6. These convert into the 
MVQ estimates reported in the same table. 
 
 
Table 6: Mean WTP per month (€) for treatment B, mean utilities and MVQ (€). Groups C-1 and C-2 
Types  Mean WTP for treatment B  p  MVQ 
  C-1 C-2    C-1  C-2 
















 Utilities       
State 22223  0.708  0.704  ns    
State 21212  0.830  0.797  ns    
  Undiscounted lifetime QALY gain
(1)      
State 22223  12.23  12.29       
State 21212  7.18  8.40       
(1) This is calculated by taking the average number of years of remaining life expectancy, based on the age 
distribution of the subsample, and weighting this by the index for the QoL gain.  
* Statistically significant differences between C-1 and C-2 at the 1% level using the t-test. 
 
The results for the WTP and utilities translate into the MVQs shown in the right hand 
columns of Table 6. For example, if the average member of the C-1 subset is willing to 
pay 83.06€ per month for 12 months, that comes to a total of 996.72€. One hundred 
individuals would therefore pay 99,672€ to prevent, on average, one case of this chronic 
illness, thereby achieving an expected benefit of 12.23 QALYs, giving an MVQ of 
8,151€, as shown in the appropriate cell in Table 6. 
 
So once again, we observe significant order effects of the kind evident in all other 
Groups. However, in three out of four comparisons, our respondents appeared to be 
responsive to the differences in risk reduction. The comparisons between MVQ of Types 
10 vs 11 and Types 12 vs 13 mostly showed no statistically significant differences – the 
only exception being the Type 10 vs 11 comparison in Group C-1, where mean WTP was 
only about 25% lower for Type 10, resulting in an MVQ which was significantly higher 
(p=0.000) for Type 11.   
 
   14
4. Second Survey: Design, Implementation and Results 
 
Given the presence of order effects in our first survey, we tried to estimate MVQ for 
some of these health gains using a between-Group design. This gave rise to a second 
survey. The second study took the four most straightforward scenarios from the first 
survey (Types 1, 3, 5 and 7) and added two more (Types 8 and 9) in order to study the 
derivation of MVQ estimates from even smaller health gains. These two scenarios were 
always presented as the second question, so they were vulnerable to being influenced by 
the response to the first question. For this reason, the final estimate of the MVQ from 
these questions will be less “clean” than from the other four questions. However, while 
acknowledging this potential problem, we thought that it was interesting to have some 
information on the MVQ derived from health gains that were even smaller than those 
used in the first survey. And since these second questions always involved 
unambiguously smaller benefits, it should have been relatively straightforward to reduce 
payments proportionally, if that is what respondents had wished to do. 
 
332 members of the general population were interviewed in person after being initially 
contacted by telephone (see Appendix 2 for characteristics of the sample). They were 
randomized between 4 subgroups. Utilities were elicited using the direct SG method. The 
framing of WTP questions was very similar to the first survey, except that the response 
format was polychotomous, involving five categories of responses (Definitely YES/NO, 
Probably YES/NO, Not Sure). Respondents were asked to allocate every amount to one 
or other of the five response categories. We present our results using only the responses 
to the “Definitely YES” category since this is a conservative estimate and it has been 
recommended (Arrow et al, 1993) to use conservative estimates in contingent valuation 
studies. Also, it has been shown (Blumenschein, 2008) that hypothetical payments are 
closer to real payments when we only use the category “Definitely YES”.  
 
The key results are summarized in Table 7. 
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Table 7: Mean WTP  (€) for treatment B and Mean Utilities. N=83 per group 
 WTP   







 D-4  MVQ 
1 163.54  --------  ------  ------- 16,407 
(12,378-22,081) 
5 ------  111.47  ------  ------ 23,487 
(16,296-32,049) 
3 ------  ------  127.37 ------ 21,777 
(16,305-26,831) 
7 -------  ------  ------  105.38 37,860 
(27,282-54,504) 
8 96.65  ------  86.98  -----  76,235 
(63,140-92,336) 
9 ------  89.72  -----  58.88  123,724 
(93,678-161,411)
 Utilities   
State 22223  .641  .701  .563  .675   
State 21212  .787  .829  .784  .793   
 
The results for the questions that were asked first in both surveys were quite similar. 
WTP for Type 1 (avoiding 22223 for 4 months) was 156.93€ in Group B-1 in the first 
survey and 163.54€ in the second survey (group D-1). WTP for Type 3 (avoiding 22223 
for 2 months) was 112.32€ in Group A-1 and 127.37€ in this survey (group D-3). These 
differences were not statistically significant. 
 
Comparing the first responses of Groups D-1 and D-3 relating to Types 1 and 3, there 
was some sensitivity to duration but it was not proportional. In the comparison between 
D-2 and D-4 relating to Types 5 and 7, there was no significant difference between 
means, despite one duration being half the other.  
 
The within-Group comparisons between the 4-month or 2-month initial scenarios and the 
2-week scenarios in the second questions all showed some degree of responsiveness – but 
again, the reductions in WTP were much less than proportional. Not surprisingly, 
therefore, the inferred MVQs show a very clear inverse relationship with duration. In the 
comparison between Types 1 vs 3, the difference is only just significantly different 
(p=0.10); but in all other cases, the differences were clearly significant (Types 1 vs 8, 
p=0.00; Types 3 vs 8, p=0.00; Types 5 vs 7, p=0.02; Type 5 vs 9, p=0.00; Type 7 vs 9, 
p=0.00). In all cases, the estimated MVQ was higher for shorter durations; and even 
though there was always a within-Group possibility of reducing the WTP for the 2-week 
duration, the MVQs derived from those questions are especially high. 
 
We also see the consequences of insufficient adjustment of WTP to the smaller QoL gain 
involved in going from 21212 to 11111 as compared with the improvement from 22223 
to 11111: the MVQs inferred from the smaller health gains are all significantly higher   16
(Types 1 vs 5, p=0.48; Types 3 vs 7, p=0.01 and 8 vs 9, p=0.00). When the insensitivity 
to duration is compounded with the insensitivity to QoL gain, the result (Type 9) is an 
estimated MVQ which is even bigger than the highest figure generated in the first survey 
as the product of payment period effects and SG chaining interacting with a smaller QoL 
gain of 2 months duration. Thus the results of the second survey reinforce concerns that 
the MVQ estimate is liable to be systematically influenced by the choice of which 





The main objective of this study was to test the robustness of various conditions that 
would need to hold if we are to obtain a reliable and reasonably all-purpose MVQ from 
questions involving different combinations of QoL, duration and risk.  
 
Our results cast quite serious doubt on the possibility of obtaining such value. Besides 
finding insufficient sensitivity to the duration of health states and the size of QoL 
improvements, we also found clear and substantial violations of procedural invariance in 
the form of order effects, payment period effects and ‘chaining effects’.   
 
The presence of order effects is well documented in the literature on contingent valuation 
(Stewart, 2002). One reaction to this problem is to assume that the less biased response is 
the first one since it cannot be influenced by the previous one(s). Given that several of the 
MVQ estimated in the first survey could have been “contaminated” by these effects, we 
conducted a second survey. In this survey, we also observed the same insensitivity even 
when we compared the MVQ estimates using only the first question. Indeed, we observed 
even greater problems, since in some groups there was almost no discrimination between 
two health gains that were clearly different.  
 
The second violation of procedural invariance was the absolute lack of sensitivity of 
monthly WTP with respect to the duration of the period of payment. Since this duration is 
quite arbitrary in many cases, the MVQ could be subject to manipulation by just 
modifying this parameter. This problem has nothing to do with all the assumptions that 
we need to make in order to elicit a unique MVQ. It is a very elementary rationality 
condition which, if not met, would undermine any serious effort to elicit these monetary 
values. Unfortunately, there is little existing evidence about this issue in the health 
economics literature. There is some more evidence on the field on environmental 
economics (Stevens, 1997; Stumborg et al., 2001). For example, Stumborg et al. (2001) 
found that total WTP for a public good was higher when the duration of payment was 10 
years as opposed to when it was 3 years (unless a 40% discount rate were assumed). If 
the period of payment is arbitrary and the total WTP changes with it, no reliable estimates 
of WTP can be elicited. However, some others have found greater sensitivity (Johnson et 
al., 2006). 
 
We also found that the particular method used (direct vs chained) to elicit health state 
utilities had a substantial impact on the MVQ computation. The indirect method raised   17
the estimate of mean utility of 21212 relative to the direct method, and thus had the effect 
of reducing the utility difference between 21212 and 11111 while at the same time 
increasing the difference between 21212 and 22223. Since these differences appear in the 
denominator of the calculation of MVQs, the effect is to increase (indeed, roughly 
double) the MVQ based on the Type 7 question while at the same time reducing (to about 
two-thirds) the MVQ based on the Type 4 question. As a consequence, the indirect 
method gives both the highest and the lowest MVQ estimates within all three Groups, 
with the former being in the region of 3 – 4 times as big as the latter.  
 
The question then is which of the two estimates (if either) better reflects preferences. It 
might be argued that direct methods should be preferred on the grounds that any biases 
generated in the SG would be compounded by chaining – and certainly, the indirect 
method is associated with greater volatility of the MVQ estimates. However, it is not 
obvious that the indirect method is producing ‘worse’ utility indices for 21212 than the 
direct method. The indirect method suggests that respondents would be willing to take a 
mean risk of death of between 5% and 8% to avoid the 21212 chronic condition – figures 
which some may view as quite high, given the aversion many people express towards 
many much smaller real-world risks. However, those figures are a good deal less than the 
means produced by the direct method – between 12% and 15%  – the latter being barely 
better than the odds in Russian Roulette. In order to decide which figure (if either) we 
should use for policy purposes we need a better descriptive theory that explains how 
people respond to these questions. Conventional wisdom assumes that people are 
Expected Utility (EU) maximisers; but the systematic disparities between direct and 
indirect estimates is incompatible with that assumption – as, indeed, is a large body of 
other evidence (see Starmer, 2000, for a review).  
 
The various ‘effects’ listed above all suggest that responses and estimates are seriously 
vulnerable to procedural influences that in theory should not make a difference. At the 
same time, there appears to be insufficient sensitivity to features of scenarios (mainly 
duration and severity) that really ought to matter and that ought to be treated 
approximately proportionally if a single MVQ is to be widely applicable. We found that 
estimates of the MVQ vary systematically with the severity of the health state used to 
elicit it, with milder health states resulting in higher estimates. We also found the 
estimates varying systematically with the duration of the health state used to elicit it, with 
shorter durations resulting in higher estimates. Overall, the patterns resemble the picture 
to which we have become used in the context of WTP for (road) safety benefits, where, 
as Jones-Lee and Loomes (2001) have noted, there is on the one hand excessive 
sensitivity to theoretically irrelevant procedural features while at the same time there 
appears to be insufficient sensitivity to those variables that really ought to be influential.  
 
Our results are in line with some other studies that have explored the relationship 
between health gains measured in QALYs and WTP. Van Houtven et al. (2006), 
expanding the Johnson et al. (1997) meta-analysis, find that WTP increases less than 
proportionately with changes in duration. Gyrd-Hansen (2003) finds that WTP is not a 
linear function of QALY values. Hammit and Haninger (2007) find that WTP is only 
29% higher for avoiding 7 days vs 1 day of moderate health problems. Donaldson et al.   18
(2008) found that WTP to avoid 12 months of a health problem was less than 4 times the 
WTP to avoid 3 months of the same health problem. Overall, it seems that our results 
reinforce previous findings and they all seem to indicate fairly strong evidence that there 
may not be a linear relationship between WTP and QALYs even for changes that might 
be considered ‘small’.  
 
However, an alternative interpretation of these findings is that the seeming lack of 
sensitivity is largely a consequence of hitting budgetary restrictions: that is, it reflects 
constraints on people’s ability to pay. This raises the problem of finding a change small 
enough to allow a linear approximation. Past research involving one of the authors 
(Pinto-Prades and Rodríguez, 2001) used even smaller health changes. For example, it 
elicited WTP to avoid 3 and 15 days in health state 11121 and 22222. Mean WTPs were 
12.5€ (3 days, 11121), 34.5€ (15 days, 11121), 65.7€ (22222, 3 days) and 99.3€ (22222, 
15 days). These means are in line with the kinds of responses used to estimate the Value 
of a Statistical Life when people are asked WTP questions for reductions in the risk of 
death
9 that are considered “marginal”. However, in none of the above cases was WTP for 
the 15 day health gain even approximately 5 times bigger than WTP for 3 days. Of 
course, it is difficult to be sure that budget constraints have no impact at all: but in many 
of the studies listed in the previous paragraph, the sums of money rarely account for more 
than a few percent of people’s annual incomes.  
 
Of course, this does not mean that our results do not suffer from this problem. To try to 
explore this possibility within our data, we took our second survey and estimated the ratio 
between WTP for 2 weeks and 2/4 months for those with income above and below the 
median. If budget constraints are a major factor, we should find that this ratio is 
considerably bigger for those with higher incomes, since their ability to express the ratio 
of benefits is less constrained. In fact, the ratio is 1.94 for those below the median income 
and 2.20 for those above the median income, a difference that it is not statistically 
significant. So while we accept that the health gains used in the present study were bigger 
than some might regard as marginal, we doubt that this is the main reason behind our 
result that MVQ increases inversely with the QALY health gain.  
 
More in line with conventional wisdom, we found only limited evidence that different 
risk reductions affect the MVQ estimates. This result is moderately encouraging – 
although it should be borne in mind that this result is somewhat out of line with evidence 
from other areas, such as the value of preventing road fatalities, where estimates often do 
vary inversely and significantly with the size of risk reduction used in the questions asked 
(for a survey of such evidence, see Beattie et al., 1998). 
 
In summary, we have found some effects that produce a wide range of MVQ estimates. 
These effects can be split into two different groups, namely: violations of the assumption 
that WTP is proportional to the health gain measured in QALYs; and violations of 
procedure invariance . The first  type of effect might be ascribed to one or more of the 
                                                 
9 For example, Tsuge et al. (2005) base their estimates of the VoSL in Japan on an average WTP of about 
200€ for a risk reduction of 1 in 10,000 in the risk of death.   19
following: a) limitations of the WTP method (e.g. the impact – to an unkown degree – of 
budget constraints); b) limitations of the QALY model (e.g. people not evaluating health 
benefits as a linear function of duration); and/or c) departures from Expected Utility 
theory (whereas utilities elicited with the SG are usually based on the assumption that 
subjects are EU maximisers). The logical follow-up to this study would involve trying to 
disentangle the relative importance of the different possible factors. For example, we 
might try to estimate the MVQ using different theoretical assumptions. There is some 
evidence (Abellán-Perpiñan et al, 2006; Bleichrodt and Pinto, 2005) suggesting that 
preferences are better represented if we assume that subjects are not EU maximisers and 
if we use a non-linear QALY model. Perhaps the volatility of the MVQ may be reduced if 
we do not use such restrictive assumptions in order to estimate it. However, it would be 
more problematic if the volatility of the MVQ estimates is due to violations of procedural 
invariance, since these effects operate outside conventional economic theory. To deal 
with them we need to understand better the psychological processes that may give rise to 
such effects.  
Overall, then, our study poses a number of quite serious challenges to the idea of finding 
a single all-purpose monetary value of a QALY. We readily acknowledge that we cannot 
disentangle all the potential reasons behind our results: indeed, given the multiplicity of 
‘effects’ and (ir)regularites identified by our design, there is every reason to believe that it 
will require a considerably larger programme of future research to do that. What we have 
been able to do is draw attention to a set of issues that are fundamental to the enterprise 
of valuing health benefits in a way that makes it possible to compare them more directly 
with other possible public sector benefits and with the costs of providing them. This is a 
topic that should be high in the research agenda of health economists. Whether or not it 
eventually turns out to be possible to establish a means of converting QALYs into money 
amounts, the exploration of the issues seems likely to give us a better understanding of 
the ways in which people value health improvements, and will thereby provide a stronger 
platform for public policy in this area.   20
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¾  I have some problems in 
walking about 
¾  I have some problems with self 
care 
¾  I have some problems in 
performing my usual activities 
(work, study, housework, family 
or leisure activies) 
¾  I have moderate pain or 
discomfort 
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Survey 1: General population = Catalonia (n=80 per Group) 
All numbers are percentages 
















  N  80 80 80 80 80 80 80   
Gender  Women  51.3 47.5 50.0 50.0 51.3 50.0 51.3  51 
Primary or 
less   42.5 52.5 45.0 38.8 43.8 40.0 47.5  61.9 
Secondary  35.0 32.5 31.3 37.5 37.5 36.3 30.0  23.3 
Educational 
Background 
University  22.5 15.0 23.8 23.8 18.8 23.8 22.5  14.7 
Active  68.8 70.0 65.0 76.3 68.8 71.3 75.0  60.7 
Retired  17.5 17.5 20.0 18.8 20.0 17.5 18.8  18.7  Working 
status 
Other  13.8 12.5 15.0  5.0  11.3 11.3  6.3  20.6 
<600€/month    30.0 30.4 31.3 23.8 21.3 26.3 20.0  13.6 
600€  -1200€ 41.3 43.0 36.3 55.0 54.7 40.0 40.0  26.8 
1200€  -1800€  21.3 21.5 27.5 11.3 20.0 22.5 30.0  17.7 
Income 
>1800€ 7.5  5.1  5.0  10.0  4.0  11.3  10.0  21.1 
18  -  40  40.0 41.3 41.3 42.5 38.8 42.5 42.5  42.0 
41  -  60  35.0 35.0 33.8 32.5 32.5 33.8 35.0  31.5  Age 
>  60  25.0 23.8 25.0 25.0 28.8 23.8 22.5  26.5 
 
Survey 2: General population = Basque country (n=83 per 
Group) 
 
    Group D-1  Group D-2  Group D-3  Group D-4  
 N  83  83  83  83 
General 
Population 
Gender Women  52.2  47.0  48.2  46.0  51.0 
Primary or less  36.1  34.9  36.1  28.9  41.3 
Vocational 20.5  25.3  14.5  25.3  24.3 
Secondary 21.6  18.1  26.5  22.9  11.1 
Educational 
Background 
University 21.7  21.7  21.7  22.9  23.4 
Active 65.1  69.9  68.7  60.2  56.5 
Retired 16.9  19.3  14.5  21.7  19.5  Working 
status 
Other 18.0  10.8  16.8  18.1  24.0 
<900€/month 20.5  12.0  19.3  18.1  19.6 
900€ -1500€  22.9  38.6  25.3  34.9  19.2 
1500€ -2100€  18.1  21.7  16.9  21.7  18.2 
Income 
>2100€ 38.6  27.7  38.6  25.3  43.0 
18 - 40  45.8  47.0  39.8  41.0  40.0 
41 - 60  30.1  27.7  41.0  32.5  33.5  Age 
> 60  24.1  25.3  19.3  26.5  26.5 
 